The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.
Dr. Butler is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center. Dr. Butler’s research focuses on clinical trials in patients with heart failure. He serves on several national committees including: the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is a recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association. Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer-reviewed cardiovascular journals and has been cited in America’s Best Doctors list.
Dr. Costanzo is the Medical Director of the Edward Center for Advanced Heart Failure and Medical Director, Heart Failure Research for the Advocate Heart Institute. She is a Fellow of the American College of Cardiology, American Heart Association and European Society of Cardiology. Dr. Costanzo is also a member of the Ordine Dei Medici (The Italian National Medical Professional Association) and a member of the Board of Directors of the Heart Failure Society of America. Dr. Costanzo has led several multi-centre randomised clinical trials, has written more than 200 papers, abstracts and articles and has presented nationally and internationally on numerous topics related to heart failure and cardiac transplantation.
G. Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. Dr. Felker’s research focus is on clinical trials in acute and chronic heart failure and the use of biomarkers as diagnostics, prognostic, and therapeutic tools in heart failure. He has published over 320 peer reviewed articles and book chapters in the field of heart failure and has served on the executive and steering committees for multiple national and international clinical trials in heart failure. Previously, he was Chief of the Heart Failure Section at Duke University School of Medicine from 2013 to 2020.
Dr. Tang is Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Dr. Tang is a practicing heart failure/transplant cardiologist specialising in specific cardiomyopathies, cardio-renal diseases, and cancer-related heart diseases. Dr. Tang is credited for unravelling the contemporary physiologic and molecular understanding of a subset of patients with cardio-renal syndrome, including the recognition of venous congestion, intra-abdominal pressure, and metabolic dysregulation as key determinants. Dr. Tang’s NIH-funded translational research focuses on understanding the mechanisms through which nitrative stress and epigenetics contribute to disease progression in heart failure and cardiomyopathy in humans, with the goal of identifying preventive treatment strategies for heart failure. Dr. Tang has authored over 630 peer-reviewed scientific manuscripts, editorials, and book chapters, which include the latest national heart failure guidelines.
Dr. Testani is Associate Professor of Medicine and Director of Heart Failure Research at Yale University School of Medicine. Dr. Testani’s primary research interest is the mechanistic understanding of cardiac-renal interactions, fluid and sodium homeostasis, and diuretic resistance in heart failure. He has over 100 peer reviewed publications with the key focus of this work understanding cardio-renal interactions in heart failure. His laboratory utilises techniques of translational research using prospective human clinical trials and large animal models to better understand mechanism and develop new therapies and diagnostics. His lab is funded by the National Institutes of Health and industry sources totaling over $15 million, and is considered by many to be amongst the top laboratories in the world in this field of study.
James E. Udelson, MD is Chief of the Division of Cardiology at Tufts Medical Center and Professor of Medicine and Radiology at Tufts University School of Medicine. Dr. Udelson’s research interests involve studying the effects of new therapeutic modalities in the setting of heart failure as well as acute and chronic coronary artery disease, and the development of imaging modalities to assess those effects. Dr. Udelson has directed and/or participated in numerous clinical trials on heart failure and cardiac imaging, focusing on the role of new therapies and how they affect remodeling, physiology, function, and outcomes. Dr. Udelson has served as a member of the FDA Medical Imaging Drugs Advisory Panel and has been invited as an ad hoc member of the FDA’s Cardiovascular and Renal Drugs Advisory Panel and the Peripheral and Central Nervous System Advisory Panel
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.